<PAGE>
Filed Pursuant to Rule 424(b)(3) and (c)
File Number 333-36152
PROSPECTUS SUPPLEMENT NO. 2 DATED September 14, 2000
to Prospectus Dated May 30, 2000
INHALE THERAPEUTIC SYSTEMS, INC.
$230,000,000
of
5% Convertible Subordinated Notes
due February 8, 2007
and
2,998,305 Shares of Common Stock
Issuable Upon Conversion of the Notes
This prospectus supplement supplements the prospectus dated May 30, 2000 of
Inhale Therapeutic Systems, Inc. relating to the public offering and sale by
selling security holders described below. This prospectus supplement contains
information on ownership of principal amount of notes beneficially owned and
offered and shares of our common stock issuable upon conversion of the notes.
This prospectus supplement should be read in conjunction with the prospectus,
and this prospectus supplement is qualified by reference to the prospectus,
except to the extent that the information provided by this prospectus supplement
supersedes the information contained in the prospectus.
SELLING SECURITY HOLDERS
The table on pages 41, 42, 43 and 44 of the prospectus setting forth information
concerning the selling security holders is amended by the addition of the
following information to that table:
<TABLE>
----------------------------------------------------------------------------------------------------------
COMMON
PRINCIPAL STOCK
AMOUNT OF COMMON STOCK OWNED
NOTES ISSUABLE UPON AFTER
BENEFICIALLY CONVERSION OF COMMON COMPLETION
OWNED AND THE STOCK OF THE
SELLING SECURITY HOLDER OFFERED(1) NOTES(1)(3) OFFERED(3) OFFERING
<S> <C> <C> <C> <C>
----------------------------------------------------------------------------------------------------------
Bank Austria Cayman Island, Ltd. $ 900,000(2) 23,464 23,464 --
----------------------------------------------------------------------------------------------------------
BNP Cooper Neff Convertible Strategies Fund,
L.P. $ 734,000 19,137 19,137 --
----------------------------------------------------------------------------------------------------------
BNP Arbitrage SNC $ 16,000(2) 417 417 --
----------------------------------------------------------------------------------------------------------
BT Equity Opportunities $ 1,000,000 26,072 26,072 --
----------------------------------------------------------------------------------------------------------
BT Equity Strategies $ 1,000,000 26,072 26,072 --
----------------------------------------------------------------------------------------------------------
Pioneer High Yield Fund $ 400,000 10,428 10,428 --
----------------------------------------------------------------------------------------------------------
Merrill Lynch, Pierce, Fenner & Smith, Inc. $ 750,000(2) 19,554 19,554 --
----------------------------------------------------------------------------------------------------------
Q Opportunity Fund, Ltd. $ 12,500,000 325,902 325,902 --
----------------------------------------------------------------------------------------------------------
Ramius Capital Group Holdings, Ltd. $ 100,000(2) 2,607 2,607 --
----------------------------------------------------------------------------------------------------------
</TABLE>
--------------------------
(1) Amounts indicated may be in excess of the total amount registered due to
sales or transfers exempt from the registration requirements of the
Securities Act since the date upon which the selling holders provided to us
in the information regarding their notes.
(2) Amounts listed are in addition to the principal amount of notes beneficially
owned and offered by the selling holder already included in the prospectus.
(3) The Board of Directors declared a two-for-one split of the outstanding
shares of our common stock for all holders of record as of the close of
business on August 1, 2000 which was effected in the form of a stock
dividend resulting in a reduction by one-half of the conversion price per
share and an increase in the number of shares of our common stock issuable
upon conversion of the notes. As of August 2, 2000 the notes became
convertible at a conversion price of $38.355 per share.
Information concerning the selling holders may change from time to time and any
changed information will be set forth in supplements to this prospectus if and
when necessary. In addition, the conversion rate and therefore, the number of
shares of common stock issuable upon conversion of the notes, is subject to
adjustment under certain circumstances. Accordingly, the aggregate principal
amount of notes and the number of shares of common stock into which the notes
are convertible may increase or decrease.
